Rita Nanda, MD, The University of Chicago Medicine

Dr Nanda on Neoadjuvant Treatment in HER2+ Breast Cancer

April 4th 2024

Rita Nanda, MD, discusses the future of neoadjuvant treatment for patients with HER2-positive breast cancer.

Therapeutic Advances in Prophylaxis Against CIN

December 3rd 2021

An overview of therapies used as prophylaxis against chemotherapy-induced neutropenia and projections on improving quality of life for patients with solid tumors with therapeutic advances.

CIN: Adopting SIMBA Therapy Into Clinical Practice

December 3rd 2021

A panel of oncologists react to their interest in using plinabulin as prophylaxis against chemotherapy-induced neutropenia in future clinical practice.

CIN: Implications of the PROTECTIVE-2 Study

November 29th 2021

Implications for treating patients with solid tumor cancers with plinabulin based on quality-of-life data and results demonstrated by the PROTECTIVE-2 trial.

CIN: Takeaways From the PROTECTIVE-1 Study

November 12th 2021

An overview of the design and results of the PROTECTIVE-1 study of plinabulin versus pegfilgrastim in patients with solid tumors receiving docetaxel myelosuppressive chemotherapy.

CIN Treatment Advances: SIMBA Therapy

November 12th 2021

What to know about plinabulin, a first-in-class selective immunomodulating microtubule-binding agent (SIMBA), in preventing chemotherapy-induced neutropenia.

CIN Prophylaxis and Bone Pain

November 12th 2021

Recommendations regarding how to best manage patients who experience bone pain from chemotherapy-induced neutropenia prophylaxis with growth factor support.

Anticancer Therapy: Safety vs Efficacy

November 5th 2021

Breast oncologists discuss how they weigh the efficacy of anticancer treatment with the possibility of a treatment-related adverse event, like chemotherapy-induced neutropenia.

Managing CIN in Patients With Breast Cancer

November 5th 2021

Preventive therapies and factors that impact how to best mitigate chemotherapy-induced neutropenia in patients with breast cancer.

Managing Chemotherapy-Induced Neutropenia With G-CSFs

October 29th 2021

Recommendations for intervening with growth factor support and important considerations for reducing or discontinuing anti-cancer therapy when patients show signs of neutropenia.

G-CSFs for Chemotherapy-Induced Neutropenia

October 22nd 2021

Breast oncologists react to the availability of granulocyte colony-stimulating factors, used as prophylaxis against chemotherapy-induced neutropenia.

CIN Prophylaxis: When to Intervene

October 22nd 2021

Variables that oncologists should consider when determining when to initiate prophylactic therapy for chemotherapy-induced neutropenia in patients with breast cancer.

Consequences of Chemotherapy-Induced Neutropenia

October 22nd 2021

A panel of breast oncologists define chemotherapy-induced neutropenia in terms of how they assess risk and attempt to prevent treatment-related toxicities in patients with cancer.

The Benefits of Tucatinib in HER2+ Breast Cancer

July 1st 2020

Understanding the HER2CLIMB Trial

July 1st 2020

A Close Look at Tucatinib in HER+ Breast Cancer

July 1st 2020

Treatment for Metastatic Breast Cancer

July 1st 2020

Dr. Nanda on Immunotherapy in Metastatic TNBC

July 18th 2015

Rita Nanda, MD, assistant professor of Medicine, associate director, Breast Medical Oncology, The University of Chicago Medicine, discusses the efficacy of pembrolizumab and atezolizumab for the treatment of patients with metastatic triple-negative breast cancer.